Clinical Trial: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naive and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT03697304) titled 'Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naive and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours' on Oct. 2, 2018.

Brief Summary: The aim of this study is to assess the efficacy of BI 754091 in combination with other checkpoint inhibitors or anticancer medications in diverse tumour type cohorts.

Study Type: Interventional

Condition: Neoplasm Metastasis

Intervention: * Drug: BI 754091

Solution for infusion

* Drug: BI 754111

Solution for infusion

* Drug: BI 891065

Tablet

Recruitment Status: Recruiting

Sponsor: Boehringer Inge...